Pipeline

PIPELINE

IntraBio is developing a number of small-molecule drug candidates that have broad applicability to rare and common neurological disorders, genetic, and inflammatory diseases.

It’s current lead drug candidate, IB1001, is initially being developed to treat three rare, genetic diseases where there are extremely high unmet medical needs: Niemann-Pick disease¬†type C, Tay-Sachs Disease, and Inherited Cerebellar Ataxias.

 

Publications